Draft:PrEP4All
 | This is a draft article. It is a work in progress open to editing by anyone. Please ensure core content policies are met before publishing it as a live Wikipedia article. Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL Last edited by Citation bot (talk | contribs) 4 days ago. (Update)
Finished drafting? or |
| Formation | 2018 |
|---|---|
| Type | Non-governmental organization |
| Purpose | HIV/AIDS |
| Website | prep4all |
PrEP4All is a national non-profit organization based in New York City, focused on ending the AIDS epidemic in the United States through the use of pre-exposure prophylaxis (PrEP).[1] In addition to fighting for access to PrEP, the organization has been active in molding the American response to COVID-19 and mpox.[2]
PrEP4All has advocated for the establishment of a PrEP program within the Centers for Disease Control and Prevention's Division of HIV Prevention.[3]
History
[edit]PrEP4All came to prominence in 2019 by uncovering that the Centers for Disease Control and Prevention held a patent for emtricitabine/tenofovir for the prevention of HIV/AIDS, and that Gilead Sciences, which marketed the medication under the brand name Truvada, was not paying royalties.[4][5]
PrEP4All noted that the 2020 agreement which allowed Teva Pharmaceuticals to manufacture a generic version of Truvada in the United States "does not guarantee it will be a cost-effective alternative" and that "the issue of PrEP access doesn't stop at the specific cost of the pill. Structural and systemic barriers like racial biases and the burden of quarterly STI testing and lab work also prevent those who are vulnerable from accessing PrEP.".[6]
See also
[edit]- Jirair Ratevosian – member of PrEP4All's board of directors
- Peter Staley – a longtime HIV/AIDS activist and a co-founder of PrEP4All
References
[edit]- ^ "Our Mission". PrEP4All. Retrieved May 20, 2025.
- ^ Trent Straube (November 29, 2022). "Leadership Changes at PrEP4All, the HIV Prevention Advocacy Group". POZ. Retrieved May 20, 2025.
- ^ Jilleen Barrett (June 23, 2022). "Over 100 HIV Groups Urge Congress to Fund a PrEP Program". POZ. Retrieved May 20, 2025.
- ^ Christopher Rowland (March 26, 2019). "Gilead profits from Tuvada HIV treatment funded by taxpayers and patented by the U.S. government". Washington Post. Retrieved May 20, 2025.
- ^ Liz Highleyman (March 28, 2019). "CDC Has Patents on PrEP, Advocates Find". POZ. Retrieved May 20, 2025.
- ^ Mathew Rodriguez (May 8, 2019). "Gilead Will Allow Generic Truvada to Hit US Market Next Year". Out. Retrieved May 20, 2025.
